Drugs / O-(2[18F]FLUOROETHYL)-L-TYROSINE
O-(2[18F]FLUOROETHYL)-L-TYROSINE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05632562 | Mar 2024 → Feb 2028 expected | malignant glioma | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02286531 | Jun 2010 → Dec 2014 | low grade glioma | University Hospital, Toulouse | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | O-(2-[18F]Fluoroethyl)-L-tyrosine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05632562 ↗ |
| Known as | [18F]-FET | “O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI” NCT05632562 ↗ |
| Known as | FET | “O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI” NCT05632562 ↗ |
| Route | Intravenous | “injected through the venous catheter” NCT02286531 ↗ |